Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque A 3-Dimensional Intravascular Ultrasound Study

Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study -

“…3 According to our statistical analysis, a final LDL cholesterol level of 1.78 mmol/L was the point where plaque volume started to decrease, but this relationship was not statistically significant (there was only a weak trend with P=0.12). This level is substantially lower than in the ESTABLISH study, 5 where it was 2.7 mmol/L and 2.86 mmol/ L in the study done by Takashima et al 19 As in the ESTABLISH study 5 and the study done by Takashima et al, 19 but not as in the study by Ishikawa et al, 20 we did not find any correlation between the percent changes…”

Association of Body Mass Index with Coronary Plaque Regression: 6-Month Prospective Study

“…The suppressive effect of statins on coronary plaque progression was more marked in studies on Japanese subjects 5,[8][9][10] , including the present report, than in previous trials using Western patients 6, 7) . Furthermore, as shown in the MEGA study 16) , designed to evaluate the effect of low-dose pravastatin (8.3 mg/ day, on average) for the primary prevention of CAD in Japanese patients, the dose effect was equivalent to 20 − 40 mg pravastatin in previous large-scale studies conducted in Western countries 17,18) .…”

“…In recent years, volumetric analysis using intravascular ultrasound (IVUS) has allowed detailed evaluation of the suppressive effects of statins against the development of coronary plaques; as a result of these studies, it has become increasingly clear that statins exert their significant suppressive effects against the development of coronary plaques by improving the serum lipid profile [5][6][7][8][9][10] …”

Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque Comparison With Atorvastatin

“…12 Subsequent multicenter studies such as the JAPAN-ACS study have verified the ESTABLISH results through investigation of strong statin-induced volume reduction of coronary plaques. [13][14][15] However, these studies have all evaluated quantitative changes of the plaques, and there have been fewer qualitative evaluations. 16 Spectral analysis of IVUS radiofrequency (RF) data can provide detailed quantitative and qualitative information on coronary plaque composition in vivo.…”